Clinical Trials
41 trialsEffect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
FB-12
NSABP Foundation Inc
Intestinal Microbiota Impact for Prognosis and Treatment Outcomes in Early Luminal Breast Cancer and Pancreatic Cancer Patients
Moscow Clinical Scientific Center
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
NSABP Foundation Inc
TONIC
The Netherlands Cancer Institute
Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer
Jilin University
The Effect of Metformin on Breast Cancer Patients
Beni-Suef University
Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
MBC1
N.N. Petrov National Medical Research Center of Oncology
Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin(PLD)
Fudan University
Breast Cancer Treatment Based on Organ-like Culture
Xijing Hospital
NeoChAI
National Cancer Center, Korea
Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant Chemotherapy
Jilin University
Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer
Shandong Cancer Hospital and Institute
Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy
Shandong Cancer Hospital and Institute
Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery
NSABP Foundation Inc
Randomized Study of Doxorubicin and Cyclophosphamide With or Without Intermittent Sunitinib in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer Patients With Measurable Primary Breast Tumor
National University Hospital, Singapore
A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer
NSABP Foundation Inc
Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer
Russian Academy of Medical Sciences
A Phase II Trial of Doxorubicin and Genexol-PM in Patients With Advanced Breast Cancer
Gachon University Gil Medical Center
Medifocus301
Medifocus, Inc.
LABC
Barretos Cancer Hospital
Correlation Between Genetic Variants and Long-term Cardiac Effects Induced by Doxorubicin in Breast Cancer Patients
National University Hospital, Singapore
Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Chemotherapy Alone in Treating Women With Stage IV Breast Cancer
National Cancer Institute (NCI)
Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer
National Cancer Institute (NCI)
Combination Chemotherapy With or Without Microwave Thermotherapy Before Surgery in Treating Women With Locally Advanced Breast Cancer
National Cancer Institute (NCI)
Validate Gene Expression and Proteomic Signatures Predictive of Treatment for Response for Breast Cancer Patient
National University Hospital, Singapore
Combination Chemotherapy in Treating Women With Breast Cancer
National Cancer Institute (NCI)
Trastuzumab or Observation After Combination Chemotherapy and Trastuzumab in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer
National Cancer Institute (NCI)
Doxorubicin or Epirubicin and Cyclophosphamide in Treating Older Women With Invasive Breast Cancer
National Cancer Institute (NCI)
Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer
National Cancer Institute (NCI)
BCSMANC
Shandong Cancer Hospital and Institute
Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.
University of Tennessee Cancer Institute
Intensive Sequential Chemotherapy With Adriamycin Taxol and Cytoxan in the Treatment of Locally Advanced Breast Cancer
King Faisal Specialist Hospital & Research Center
AX Versus AC as Adjuvant Treatment for Node-Negative Breast Cancer
Peking Union Medical College Hospital
Doxorubicin Hydrochloride, Cyclophosphamide, Docetaxel, and S-1 Before Surgery in Treating Women With Stage II or Stage III Breast Cancer
National Cancer Institute (NCI)
Cyclophosphamide and Docetaxel or Doxorubicin in Treating Women With Newly Diagnosed Breast Cancer That Can Be Removed by Surgery
National Cancer Institute (NCI)
Trial of Myocet in Metastatic Breast Cancer
Sopherion Therapeutics
Combination Chemotherapy With or Without Darbepoetin Alfa in Treating Women With Stage III Breast Cancer
National Cancer Institute (NCI)
Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast Cancer
Fudan University
Myocet, Docetaxel & Trastuzumab as 1st Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer
Zeneus Pharma